Immediate Implant Placement Using Xenograft Mixed with Vitamin D Versus Hyaluronic Acid.
Condition(s) studied
Investigational drug(s) / intervention(s)
Hyaluronic Acid (HA): Hyaluronic acid is one of the essential components of extracellular matrix, which plays a predominant role in tissue morphogenesis, cell migration, differentiation, and adhesion. It has been recently reported that hyaluronic acid increases osteoblastic bone formation in vitro through increased mesenchymal cell differentiation and migration. It has demonstrated that Hyaluronic acid not only acted as a carrier of growth factors and cell but also stimulated bone formation through chemotaxis, proliferation and differentiation of mesenchymal cells into osteoblasts. Although Hyaluronic acid shares bone induction properties with growth factors as bone morphogenic protein 2 and osteopontin
Vitamin D: It was shown that locally applied vitamin D3 in combination with bovine bone mineral matrix improved the bone formation and strengthened the site of the fracture in ovariectomized rats. Local application of vitamin D3 also proved to be promising in promoting osteo- genesis and mineralization for restoration of bone defects. Grounding on this incites, it has been suggested that vitamin D3 might exert a positive local effect on alveolar bone regeneration
Study summary
Immediate implant placement using xenograft as space filling material mixed with vitamin D versus hyaluronic acid in posterior mandible region This study aims to evaluate implant stability and density after placement of immediate implant and Xenograft mixed with Hyaluronic acid or Vitamin D at posterior mandible region
Eligibility
Primary outcome measure(s)
- Implant secondary stability — after 6 months
To evaluate the implant stability by Any-check device.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Faculty of dentistry ,Cairo university | Cairo | Egypt | Recruiting |
More Cairo University trials in Egypt
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06842368 on ClinicalTrials.gov ↗ ← All trials in Egypt